The Canadian Journal of Neurological Sciences

Le Journal Canadien des Sciences Neurologiques

The Official Journal of

The Canadian Neurological Society
The Canadian Neurosurgical Society
The Canadian Society of Clinical Neurophysiologists
The Canadian Association for Child Neurology

Volume 13, No. 3 **August 1986**



FOR THE VASCULAR HEAD PAIN PUZZLE

CAFERGOT®
To ABORT acute vascular headache

SANDOMIGRAN® DS
PROPHYLAXIS for chronic recurring vascular headache

SANDOZ®
Complete headache therapy
Sandoz Canada Inc., Dorval, Quebec H9R 4P5

Cafergot contains: ergotamine tartrate/caffeine ®TM
Sandomigran DS contains: pizotyline
Full prescribing information available on request. PAAB CCPP PMAC ACIM

https://doi.org/10.1017/S0317167100036258 Published online by Cambridge University Press

The Canadian Journal of Neurological Sciences

Le Journal Canadien des Sciences Neurologiques

The Official Journal of:/La Revue Officielle de:

The Canadian Neurological Society
La Société Canadienne de Neurologie
President/Président — T. Peter Seland
Secretary-Treasurer/ — William McCormick,
Secrétaire-Trésorier Box 2148, Dickson Centre,
Victoria General Hospital,
Halifax, Nova Scotia
B3H 2Y9

The Canadian Neurosurgical Society
La Société Canadienne de Neurochirurgie
President/Président — Francis E. LeBlanc
Secretary-Treasurer/ — Alain Godon,
Secrétaire-Trésorier 12361 Notre-Dame-des Anges St.,
Montreal, Quebec
H4J 2C3

The Canadian Society of Clinical Neurophysiologists
La Société Canadienne de Neurophysiologues Clinics
President/Président — R. Gordon Blair
Secretary-Treasurer/ — Werner J. Becker,
Secrétaire-Trésorier 841 Centre Avenue East,
Calgary, Alberta
T2E 0A1

The Canadian Association for Child Neurology
L'Association Canadienne de Neurologie Pédiatrique
President/Président — Robert H.A. Haslam
Secretary-Treasurer/ — Daniel Keene,
Secrétaire-Trésorier Suite 208, 150 Montreal Road,
Vanier, Ontario
K1L 8H2

The Canadian Journal of Neurological Sciences is published quarterly by University of Calgary Press. The annual subscription rate is $40.00 for Canada and the U.S.A. $44.00 elsewhere. Interns, Residents Pre- and Post-Doctoral Students $20.00 per annum. Single copies $12.00 each. All communications and subscriptions should be sent to the Editor, Canadian Journal of Neurological Sciences, Room 1496, Faculty of Medicine, University of Calgary, 3330 Hospital Drive N.W., Calgary, Alberta, Canada T2N 4N1. Telephone: (403) 220-3062.

Mailed under second class registration number 3307. Postage paid at Calgary, Alberta. This journal is indexed by Index Medicus, Excerpta Medica and Current Contents — Clinical Practice and Life Sciences.

Le Journal Canadien des Sciences Neurologiques est publié trimestriellement par les Presses de l'Université de Calgary. L'abonnement annuel est de $40.00 pour le Canada et les Etats-Unis; $44.00 ailleurs. Internes, résidents, fellows pré et post-doctoral: $20.00 par an. Toutes les communications et les abonnements doivent être adressés à l'Editeur, Journal des Sciences Neurologiques, chambre 1496, Faculté de Médecine, Université de Calgary, 3330 Hospital Drive N.W., Calgary, Alberta, T2N 4N1. Téléphone (403) 220-3062.

Posté sous permis de second classe no 3307. Port payé à Calgary, Alberta. Le Journal est cité et indexé dans Index Medicus, Excerpta Medica et Current Contents — Clinical Practice et Life Sciences.

Advertising representative/Représentant de publicité Keith Health Care Communications,
4953 Dundas St. W., Toronto, Ontario, Canada M9A 1B6 — (416) 239-1233

Printer/Imprimeur McAra Printing Limited, 105, 2507 - 12th Street N.E., Calgary, Alberta T2E 7L5

ISSN 0317 - 1671

CONFRONT THE REALITIES OF PARKINSON'S DISEASE

Problems of long-term therapy with levodopa compounds

- ☐ Performance fluctuations
- ☐ Early morning stiffness
- ☐ End-of-dose deterioration
- ☐ On-off phenomenon

During the course of a day[1]



Once a clear pattern is determined, two treatment approaches are possible:

- ☐ Add "PARLODEL"

and/or

- ☐ More frequent, smaller doses of levodopa

https://doi.org/10.1017/S0317167100036258 Published online by Cambridge University Press

https://doi.org/10.1017/S0317167100036258 Published online by Cambridge University Press

LISTED ON ALL PROVINCIAL FORMULARIES

ADD PARLODEL®

(bromocriptine mesylate)

For added control

ACTIONS Parlodel (bromocriptine mesylate) is a dopaminomimetic ergot derivate with D_2 type dopamine receptor agonist activity, and has also D_1 dopamine receptor antagonist properties. The dopaminomimetic activity of bromocriptine in the striatum is considered responsible for the clinical benefits seen in selected patients with Parkinson's Disease, when low doses of the drug are gradually added to levodopa therapy in patients on long-term treatment who develop late side effects of levodopa or no longer respond to the medication. Excessive dopaminomimetic drive may, however, provoke psychotic and other adverse reactions.

The extreme variability in G.I. tract absorption, and the extensive and individually variable first-pass metabolism is responsible for the broad variability in plasma concentrations of bromocriptine and, in part, for the variability in dose response.

INDICATIONS* Parkinson's Disease: Parlodel (bromocriptine mesylate) has been found to be clinically useful as an adjunct to levodopa (usually with a decarboxylase inhibitor), in the symptomatic management of selected patients with Parkinson's Disease who experience prominent dyskinesia or wearing off reactions on long-term levodopa therapy.

Patients on long-term treatment who are beginning to deteriorate on levodopa therapy may be controlled by reducing the dose of levodopa and adjusting the frequency and schedule of drug administration. Patients maintained on optimal dosages of levodopa who still experience prominent dyskinesia and/or end-of-dose failure, may benefit from the concomitant use of Parlodel, by decreasing the occurrence and/or severity of these manifestations. Since rapid escalation of bromocriptine doses causes severe adverse reactions, it is recommended to combine a slow increase of Parlodel, usually with a concomitant, gradual and limited reduction of levodopa dosage. Continued efficacy of bromocriptine for more than two years has not been established and there is some evidence that its efficacy tends to wane. Evidence available indicates that there is no consistent benefit from bromocriptine in patients who have not responded previously to levodopa, and studies have shown significantly more adverse reactions in bromocriptine treated patients than in patients treated with levodopa. Parlodel is not recommended in the treatment of newly diagnosed patients or as the sole medication in Parkinson's Disease.

CONTRAINDICATIONS Other than sensitivity to ergot alkaloids, no absolute contraindications to treatment with Parlodel (bromocriptine mesylate) are known. For procedure during pregnancy see "Use in Pregnancy" under Precautions.

WARNINGS Long-term treatment (6-36 months) with Parlodel in doses of 20 to 100 mg/day has been associated with pulmonary infiltrates, pleural effusion and thickening of the pleura in a few patients. Where Parlodel was discontinued, these changes slowly reverted to normal.

PRECAUTIONS Parlodel (bromocriptine mesylate) may cause hypotension, primarily postural; periodic monitoring of the blood pressure, particularly during the first days of therapy, is advisable. In some patients *dizziness* (vertigo) may occur with Parlodel; patients should therefore be cautioned against activities requiring rapid and precise responses such as driving an automobile or operating dangerous machinery until their response has been determined.

Care should be exercised when administering Parlodel concomitantly with phenothiazines or antihypertensive agents. Due to drug interaction at the receptor site, dosage should be adjusted accordingly.

Alcohol should be avoided during treatment with Parlodel. In some patients, the concomitant use of Parlodel and alcohol has given rise to alcohol intolerance and an increase in the severity and incidence of Parlodel's possible adverse reactions.

Parlodel should always be taken with food. In cases where severe adverse effects, such as nausea, vomiting, vertigo or headaches are severe or persisting, the therapeutic dosage of Parlodel should be reduced to one-half tablet daily (1.25 mg) and increased gradually to that recommended.

As with all medication, Parlodel should be kept safely out of the reach of children.

Use in Pregnancy If the patient wishes to become pregnant, Parlodel (bromocriptine mesylate) should be stopped as soon as possible after conception is suspected. In this event immunological confirmation should be done immediately. When pregnancy is confirmed, Parlodel, like all other drugs, should be discontinued unless, in the opinion of the treating physician, the possible benefit to the patient outweighs the potential risk to the fetus.

In human studies with Parlodel (reviewed by Turkalj, I.), there were 1410 reported pregnancies, which yielded 1236 live and 5 stillborn infants from women who took Parlodel (bromocriptine mesylate) during early pregnancy. Among the 1241 infants, 43 cases (31 minor and 12 major) of congenital anomalies were reported. The incidence (3.46%) and type of congenital malformations and the incidence of spontaneous abortions (11.13%) in this group of pregnancies does not exceed that generally reported for such occurrences in the population at large.

Gynecological Supervision All women patients receiving Parlodel continuously for six months or more should have a gynecological examination before therapy, yearly if still menstruating, and six-monthly if menopausal. The examination should include cervical and, if possible, endometrial cytology. Post-menopausal women on estrogen therapy should be excluded from Parlodel therapy at the discretion of the physican because estrogen induced uterine bleeding may mask the presence of pathological lesions.

A lifetime rat study revealed that some animals developed uterine tumors and endometrial carcinoma thought to be due to a state of induced estrogen dominance. However, clinical experience in women with a variety of hyperprolactinemic and other conditions, treated with Parlodel for months or years, failed to demonstrate abnormal trends in hormonal levels or in endometrial cytology.

Normoprolactinemic women treated with Parlodel should be given the lowest effective dose necessary to relieve their symptoms, in order to avoid the possibility of suppression of prolactin below normal levels, with a consequent impairment of luteal function.

Use in Parkinson's Disease: Use of Parlodel (bromocriptine mesylate), particularly in high doses, may be associated with mental confusion and mental disturbances. Since patients with Parkinson's Disease may manifest varying degrees of dementia, caution should be exercised when treating such patients with Parlodel.

Parlodel administered alone or concomitantly with levodopa may cause visual or auditory hallucinations. These usually resolve with dosage reduction, but discontinuation of Parlodel may be required in some cases. Rarely, after high doses, have hallucinations persisted for several weeks following discontinuation of Parlodel. Caution should be exercised when administering Parlodel to patients with a history of myocardial infarction, particularly if they have a residual atrial, nodal or ventricular arrhythmia.

Symptomatic hypotension can occur and, therefore, caution should be exercised when administering Parlodel, particularly in patients receiving antihypertensive medication. Periodic evaluation of hepatic, hematopoietic, cardiovascular and renal function is recommended.

Drug Interactions: The concomitant use of erythromycin may increase bromocriptine plasma levels.

ADVERSE REACTIONS The most frequently observed adverse reactions are nausea, vomiting, headache and gastrointestinal side effects such as abdominal pain, diarrhea and constipation. All these effects may be minimized or even prevented by giving small initial doses of bromocriptine and by taking it with food.

Postural hypotension which can, on rare occasions, lead to fainting and "shock-like" syndromes have been reported in sensitive patients. This is most likely to occur during the first few days of Parlodel treatment.

When bromocriptine is added to levodopa therapy, the incidence of adverse reactions may increase. The most common newly appearing adverse reactions in combination therapy were: nausea, abnormal involuntary movements, hallucinations, confusion, "on-off" phenomenon, dizziness, drowsiness, faintness, fainting, vomiting, asthenia, abdominal discomfort, visual disturbance, ataxia, insomnia, depression, hypotension, shortness of breath, constipation and vertigo.

Less common adverse reactions include, anorexia, anxiety, blepharospasm, dry mouth, dysphagia, edema of the feet and ankles, erythromelalgia, epileptiform seizures, fatigue, headache, lethargia, mottling of skin, nasal stuffiness, nervousness, nightmares, parethesia, skin rash, urinary frequency, urinary incontinence, urinary retention and rarely signs of symptoms of ergotism such as tingling of fingers, cold feet, numbness, muscle cramps of feet and legs or exacerbation of Raynaud's syndrome.

Abnormalities in laboratory tests may include elevation of blood urea nitrogen, SGOT, SGPT, GGPT, CPK, alkaline phosphatase and uric acid, which are usually transient and not of clinical significance.

The occurrence of adverse reactions may be lessened by temporarily reducing dosage to one-half tablet two or three times daily.

SYMPTOMS AND TREATMENT OF OVERDOSE
There have been several reports of acute overdosage with Parlodel (bromocriptine mesylate) in children and adults. No life threatening reactions have occurred. Symptoms reported included nausea, vomiting, dizziness, drowsiness, hypotension, sweating and hallucinations. Management is largely symptomatic; the cardiovascular system should be monitored. Metoclopramide can be used to antagonize the emesis and hallucinations in patients who have taken high doses.

DOSAGE AND ADMINISTRATION Parlodel (bromocriptine mesylate) should always be taken with food.

Although Parlodel (bromocriptine mesylate) has been found clinically useful in decreasing the severity and frequency of "on-off" fluctuations of late levodopa therapy, the decision to use bromocriptine as adjunctive treatment and the selection of dosage must be individualized in each case. A low dose is recommended. The initial dose of Parlodel is one half of a 2.5 mg tablet (1.25 mg) at bedtime with food to establish initial tolerance. Thereafter, the recommended dosage is 2.5 mg daily in two divided doses, with meals, (half a 2.5 mg tablet twice daily). The dosage may be increased very gradually, if necessary, by adding an additional 2.5 mg per day, once every 2 to 4 weeks, to be taken always in divided doses with meals. Increments should usually never exceed 2.5 mg. Clinical assessments are recommended at two week intervals or less during dosage titration, to ensure that the lowest effective dosage is not exceeded. The usual dosage range is from a few milligrams to 40 mg daily in two or three divided doses with meals. The median dose varies with the experience of individual investigators, but can be around 10 mg daily or higher. During initial titration it is recommended that the dosage of levodopa should be maintained, if possible. Subsequently, it might be desirable to combine a slow increase of bromocriptine with a concomitant, limited and gradual reduction of levodopa.

AVAILABILITY

1. TABLETS each containing 2.5 mg bromocriptine, as mesylate, available in bottles of 100.

   Scored 7 mm, round compressed white tablets with "XC" on one side and "PARLODEL" on the reverse.
2. CAPSULES each containing 5 mg bromocriptine, as mesylate, available in bottles of 100. Caramel and white size 3 hard shell capsules with "PARLODEL" on one side and "5 mg" on the other.

REFERENCES:

1. Grimes J.D. Medical Review Series (Handbook No. 4) 1984;14
2. Hoehn M, Elton RL. Low dosages of bromocriptine added to levodopa in Parkinson's disease. Neurology 1985;35:199-206

2.5 mg
scored tablet

5 mg
capsule

PAAB
CCPP

* For information on other approved indications, please consult the Parlodel product monograph, available to physicians and pharmacists on request.

SANDOZ

Sandoz Canada Inc.
Dorval, Quebec
H9R 4P5

https://doi.org/10.1017/S0317167100036258 Published online by Cambridge University Press

https://doi.org/10.1017/S0317167100036258 Published online by Cambridge University Press

For brief prescribing information see page xvi

https://doi.org/10.1017/S0317167100036258 Published online by Cambridge University Press

https://doi.org/10.1017/S0317167100036258 Published online by Cambridge University Press

HOLD IT!

For the treatment of Parkinson Syndrome – "levodopa, combined with a decarboxylase inhibitor, remains the best treatment for most patients."[1]

In most Parkinsonian patients 'Prolopa':

- ☐ improves motor movement rapidly[2]
- ☐ achieves high serum levels quickly[2]
- ☐ minimizes common side effects like nausea and vomiting
- ☐ all three 'Prolopa' dose forms contain the established 4:1 ratio

The use of the 4:1 levodopa/decarboxylase inhibitor combination has been shown to reduce significantly the incidence of side effects attributed to the 10:1 ratio[3,4,5]

Prolopa®
(levodopa/benserazide) 4:1

Helps return the simple pleasures of living.

ROCHE®

For brief prescribing information see page xix

https://doi.org/10.1017/S0317167100036258 Published online by Cambridge University Press

Information for Authors

The Canadian Journal of Neurological Sciences publishes original articles in the clinical and basic neurosciences. Manuscripts are considered for publication with the understanding that, except for identified review articles, they have not been published elsewhere except in abstract form and are not under simultaneous consideration by another publication. Manuscripts should be submitted to:

The Editor
Canadian Journal of Neurological Sciences
Faculty of Medicine,
University of Calgary
3330 Hospital Drive N.W.
Calgary, Alberta T2N 4N1

Manuscripts and all illustrations should be submitted in triplicate. Papers will be accepted in English or French. All papers should be accompanied by an abstract or a résumé of approximately 150 words on a separate page, preferably in both languages, although the Journal will provide the translation if requested. All manuscripts should be double spaced throughout, including references and legends for illustrations. Margins of at least 25 mm should be left on all sides.

For detailed instructions regarding style and layout, authors should refer to "Uniform requirements for manuscripts submitted to biomedical journals". Copies of this document may be obtained by writing to the Journal office, but the main points will be summarized here. Articles should be subdivided under conventional headings of "introduction", "methods and materials", "results" and "discussion" but other headings and subheadings will be considered if more suitable for a particular manuscript. A title page should identify the title of the article, authors, name of institution(s) from which the work originated, and the address and telephone number of the author to whom communications should be addressed. Pages of text should be numbered consecutively. Acknowledgements, including recognition of financial support, should be typed on a separate page at the end of the text.

References are to be numbered in the order of citation in the text. Those cited only in tables or in legends for illustrations are numbered in accordance with a sequence established by the first identification in the text of a particular table or illustration. Titles of journals should be abbreviated according to the style used in Index Medicus. References should be complete including the names of the first three authors followed by "et al" if there are more than three authors, full title, year of publication, volume number, and inclusive pagination for journal articles. Book or chapter references should also include the place of publication and name of the publisher. Examples of correct forms of references follow:

Journals

Poirier LJ, Filion M, Larochelle L, et al. Physiopathology of experimental parkinsonism in the monkey. Can J Neurol Sci 1975; 2: 255-263

Chapter in a book

McGeer PL, McGeer EG. Amino acid neurotransmitters. In: Siegel GJ, Albers RW, Agranoff BW, Katzman R, eds. Basic Neurochemistry. Boston: Little, Brown & Co, 1981: 233-254

Illustrations should be high quality glossy black-and-white photographic prints, preferably 127 x 173 mm (5 x 7"). Original artwork and radiographs should not be submitted. The additional cost of colour illustration must be borne by the author; quotations are available upon request from the Journal office. All figures should be identified on the back with the author's name and figure number. Letters and arrows applied to the figures to identify particular findings should be professional appliques suitable for publication. Photomicrographs should include a calibration bar with the scale indicated on the figure or in the legend. Legends for illustrations should be typed on a separate page from the illustrations themselves.

Tables should each be on a separate page and be identified with the title or heading. Particular care should be taken in the preparation of tables to ensure that the data are presented in the most clear and precise format. Each column should have a short or abbreviated heading. Place explanatory matter in footnotes, not in the heading. Do not submit tables as photographs.

The SI system (système international d'unités) should be used in reporting all laboratory data, even if originally reported in another system. Temperatures are reported in degrees Celsius. Other measurements should be reported in the metric system. English language text may use either British or American spelling, but should be consistent throughout.

Review articles on selected topics also are published by the Journal. These are usually invited, but unsolicited reviews will be considered. It is suggested that authors intending to submit reviews contact the Editor in advance.

Letters to the Editor are welcome. These should be limited to two double-spaced pages and may include one illustration and a maximum of four references.

https://doi.org/10.1017/S0317167100036258 Published online by Cambridge University Press

Information aux Auteurs

Le Journal Canadien des Sciences Neurologiques publie des articles originaux dans les sciences neurologiques, cliniques et fondamentales. Les manuscrits ne sont considérés pour publication qu'à la condition expresse, à l'exception des articles de revue clairement identifiés comme tel, qu'ils n'aient pas été publiés ailleurs, sauf sous forme de résumé et qu'ils ne soient pas sous considération simultanée par un autre journal. Les manuscrits doivent être soumis à:

L'Editeur
Journal Canadien des Sciences Neurologiques,
Faculté de Médecine,
Université de Calgary,
3330 Hospital Drive, N.W.,
Calgary, Alberta T2N 4N1

Les manuscrits et toutes les illustrations doivent être soumis en triplicata. Les articles seront acceptés en français ou en anglais. Tous les articles doivent être accompagnés d'un résumé d'environ 150 mots, sur page séparée, préférablement dans les deux langues, quoique le Journal puisse fournir cette traduction sur requête. Les manuscrits doivent être dactylographiés complètement à double interligne y compris les références et les légendes pour illustrations. Des marges d'au moins 25 mm doivent être laissées de tous les côtés.

Pour les conseils plus détaillés sur le style et la présentation du texte, les auteurs doivent se référer au texte intitulé "Règlements uniformes pour les manuscrits soumis aux journaux biomédicaux". On peut obtenir une copie de ce document en écrivant au bureau du Journal, mais en voici les principaux points: Les articles doivent être présentés selon le plan habituel: "Introduction", "Matériel et méthodes", "Résultats" et "Discussion", mais il est possible d'employer d'autres titres ou sous-titres si nécessaire pour un manuscrit en particulier. Sur une page titre séparée on doit identifier le titre de l'article, les auteurs, les institutions d'où origine le travail, ainsi que l'adresse et le numéro de téléphone de l'auteur à qui devront être adressées les communications. Les remerciements, incluant ceux pour l'appui financier, doivent être dactylographiés sur page séparée à la fin du texte. Les références doivent être numérotées dans l'ordre où elles sont citées dans le texte. Celles qui sont citées seulement dans les tableaux ou légendes d'illustrations sont numérotées selon la séquence établie par la première identification dans le texte de ces tableaux ou illustrations particulières. Les titres des Journaux doivent être abrégés selon le style utilisé dans Index Medicus. Les références doivent être complètes, incluant le nom des trois premiers auteurs suivis de "et al", s'il y a plus de trois auteurs, le titre complet, l'année de publication, le numéro du volume et les premières et dernières pages de l'article. Les références aux livres et chapitres de livres doivent aussi inclure le lieu de la publication et le nom de la maison d'édition. Les exemples corrects suivants peuvent être utilisés:

Journaux

Poirier LJ, Filion M, Larochelle L, et al. Physiopathology of experimental parkinsonism in the monkey. Can J Neurol Sci 1975; 2: 255-263

Chapitre de livre

McGeer PL, McGeer EG, Amino acid neurotransmitters. In: Siegel GJ, Albers RW, Agranoff BW, Katzman R, eds. Basic Neurochemistry. Boston: Little, Brown & Co, 1981: 233-254

Les **illustrations** doivent être sur papier brillant de haute qualité et imprimés en blanc et noir, préférablement 127 x 173 mm (5 x 7"). Les illustrations et photographies originales ne doivent pas être soumises. Le coût supplémentaire des illustrations en couleur revient entièrement à l'auteur; les coûts détaillés peuvent être obtenus directement au bureau du Journal. Il faut identifier toutes illustrations en inscrivant au dos le nom de l'auteur et le numéro. Toutes lettres ou flèches appliquées aux illustrations pour identifier un aspect particulier doivent être de qualité professionnelle. Les photomicrographies doivent inclure une barre de calibration dont l'échelle est mentionée dans la légende. Les légendes des illustrations doivent être dactylographiées sur une page séparée de celles-ci.

Les **tableaux** doivent être sur des pages séparées et être identifiés avec titre. On doit prendre un soin particulier dans la préparation de ces tableaux afin d'assurer que les données soient présentées avec le format le plus clair et le plus précis possible. Chaque colonne doit avoir un court titre. Les explications doivent être placées en dessous du tableau et non en sous-titre. Un tableau ne doit pas être soumis sous forme de photographie.

On doit employer le système international d'unités (SI) pour toutes données de laboratoire, même si celles-ci sont originellement présentées dans un autre système. Les températures doivent être citées en degrés Celcius. Les autres données doivent utiliser le système métrique. Les textes en anglais peuvent utiliser l'orthographe anglais ou américain, mais cet usage doit être constant.

Le Journal publie également des **articles de revue** sur des sujets sélectionnées. Ces articles sont généralement sur invitation, mais, à l'occasion, une revue non sollicitée peut être acceptée. Il serait préférable que les auteurs ayant l'intention de soumettre une telle revue contactent d'abord l'Editeur.

Nous accueillons les **lettres à l'Editeur**. Celles-ci doivent se limiter à deux pages, double interligne et peuvent contenir une seule illustration et ne citer qu'un maximum de quatre références.

https://doi.org/10.1017/S0317167100036258 Published online by Cambridge University Press

Introducing the Nicolet CA2000

Comprehensive Electrodiagnostics In the Nicolet Tradition of Quality



Comprehensive Testing Capabilities

- Auditory Evoked Potential Testing: ABR, ECoG, MLR, 40 Hz, LLR, P300
- Visual Evoked Potential Testing: VEP, ERG, EOG
- Somatosensory Evoked Potential Testing: SEP, Dermatomes
- Facial Nerve Testing and Monitoring
- Electromyographic Testing: Needle EMG, NCV, F-Wave, H-Reflex, Repetitive Stimulation
- Electronystagmographic Testing
- Intraoperative Monitoring

Our Commitment to Quality

In addition to providing you with a variety of hardware and software features, all of our electrodiagnostic systems are backed by:

- A full one-year warranty
- Comprehensive customer training
- Experienced full-time applications staff
- Our national/international service network
- Factory-trained service personnel
- Thorough, easy-to-read documentation
- Nicolet's 18 years of experience in the biomedical field

Additional Information

To learn more about the Nicolet CA2000 or to schedule a demonstration, call **1-416-625-8302**
Nicolet Instrument Canada Inc.
1-1200 Aerowood Drive,
Mississauga, Ontario
L4W 2S7

Nicolet
Electrophysiology
Yesterday, Today, Tomorrow

https://doi.org/10.1017/S0317167100036258 Published online by Cambridge University Press

American Epilepsy Society — American Electroencephalographic Society
Joint Fortieth Anniversary Meeting
November 15-22, 1986 — Seattle, Washington

DIDACTIC COURSES & WORKSHOPS	
November 15	Course: State of the Science in EEG, Evoked Potentials and Clinical Neurophysiology
November 16	Course: EEG as Related to Epilepsy; Pathophysiology of Epilepsy
November 17	Course: Clinical Pharmacology of Antiepileptic Drugs Investigators' Workshops: Debates on Controversial Issues Kindling, Experimental Models, Ictal-like Events in the Slice, Seizure Networks Evening: Surgery for Childhood Epilepsy, Topographic Mapping, Welcoming Reception
SCIENTIFIC PROGRAM	
November 18	American EEG Society Presidential Address; Herbert H. Jasper Award Symposium I: Basic Mechanisms of Antiepileptic Drug Action; Poster & Platform Presentations Dinner Workshops: The Approach to EEG-Clinical Problems in Childhood; The EEG in Pre-Senile Dementias, Senility and Senescence; Motor Evoked Potentials; Computers and Data Bases
November 19	American Epilepsy Society Lennox Award and Lecture, Lennox Fellow and AES Award Symposium II: Sleep and Seizure Disorders; Poster & Platform Presentations Evening: Special Interest Groups
November 20	Symposium III & IV: Newer Applications of Evoked Potentials; Surgery of the Corpus Callosum Poster & Platform Presentations Evening: 40th Anniversary Reception and Banquet
OTHER	
November 21	Merritt-Putnam Symposium: Pediatric Neurology, co-sponsored by Columbia University, AES and EFA
November 22	AES Symposium: Epilepsy and Behavior
CONTACT:	American Epilepsy Society, 179 Allyn Street Suite 304, Hartford, CT 06103 (203-246-6566) OR American EEG Society, 2579 Melinda Drive NE Atlanta, GA 30345 (404-320-1746)
ACCREDITATION:	This meeting is designed to provide an update for the academic neuroscientist and neurologist, practicing neurologist, neurosurgeon, internist and pediatrician. Both societies are accredited by the Accreditation Council for Continuing Medical Education (ACCME) to sponsor continuing medical education for physicians. This CME activity is designated as meeting the criteria for up to 35 hours in Category I of the Physician's Recognition Award of the AMA.

HANS BERGER POSTDOCTORAL FELLOWSHIP OF THE AMERICAN EEG SOCIETY

The American EEG Society is pleased to announce a new postdoctoral fellowship award: the Hans Berger Research Fellowship. The one year fellowship award of $25,000 is intended to provide an additional postdoctoral fellowship year for an M.D. who has completed his specialty training and is currently a Clinical Neurophysiology postdoctoral fellow in North America, but who requires an additional year to complete a clinical or basic research project. Deadline for receipt of fellowship applications is February 1, 1987, for an award beginning July 1, 1987. The recipient of the fellowship award will be announced during the month of March. Further information can be obtained from Fay S. Tyner, Executive Director, American EEG Society, 2579 Melinda Drive, N.E., Atlanta, GA 30345.

(supported in part by matching funds contributed by Nihon-Kohden, Oxford Medilog, Neuro-Science and Raven Press).

WILLIAM G. LENNOX POSTDOCTORAL FELLOWSHIP IN EPILEPSY OF THE AMERICAN EPILEPSY SOCIETY

A one year William G. Lennox Postdoctoral Fellowship will be awarded in 1987 to a selected applicant with interests in epilepsy research. The Fellowship provides a stipend of $25,000 and support to attend the yearly meeting following completion of the Fellowship. The Lennox Fellow is expected to present the results of his/her work at that time.

Candidates must have completed their doctoral training (Ph.D., M.D., or equivalent degree) by the time the Fellowship would begin. To apply, submit a Curriculum Vitae, a list of publications, and a letter from the sponsor (additional letters of reference are optional). Also, the proposed research should be described (which may relate to any aspect of epilepsy), including goals, scientific background, methods, significance, and research facilities available to support the project. This description should not exceed five pages. There is no formal application form.

Deadline for receipt of materials is **February 1, 1987,** for the Fellowship beginning July-September, 1987. Send materials (six copies) to: American Epilepsy Society, 179 Allyn Street, Suite 304, Hartford, CT 06103.

https://doi.org/10.1017/S0317167100036258 Published online by Cambridge University Press